FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Giovanni Barosi

Research Profile

Disorders

Chemicals & Drugs

Physiology

Geographic Areas

Italy

Anatomy

Procedures

Activities & Behaviors

Cost Benefit Analysis

Co-author Network

Publications

TOP 3
Guido Finazzi; Maria Chiara Finazzi; Giuseppe Fioritoni; Vincenzo Martinelli; Caterina Musolino; Francesco Nobile; Odoardo Maria Olimpieri; Enrico Maria Pogliani; Tiziano Barbui; Giovanni Barosi; Daniela Cilloni; Tim Demuth; Marco Ruggeri; Piera Sivera; Giorgina Specchia; Silvia Di Tollo; Alessandro M Vannucchi; Alessandro Rambaldi
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy.
Maria Zingariello; Rosa Alba Rana; Laura Sancillo; Giovanni Barosi; Fiorella Ciaffoni; Emanuela D'Amore; Barbara Ghinassi; Judith D Goldberg; Xiaochun Li; Fabrizio Martelli; Francesca Masiello; Margherita Massa; Anna Rita Migliaccio
Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.
Stefania Badalucco; Giovanni Barosi; Rita Campanelli; Paolo Catarsi; Christian Andrea Di Buduo; David L Kaplan; Margherita Massa; Isabella Pallotta; Vittorio Rosti; Alessandra Balduini
Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Giovanni Barosi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Guido Finazzi; Maria Chiara Finazzi; Giuseppe Fioritoni; Vincenzo Martinelli; Caterina Musolino; Francesco Nobile; Odoardo Maria Olimpieri; Enrico Maria Pogliani; Tiziano Barbui; Giovanni Barosi; Daniela Cilloni; Tim Demuth; Marco Ruggeri; Piera Sivera; Giorgina Specchia; Silvia Di Tollo; Alessandro M Vannucchi; Alessandro Rambaldi
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy.
British journal of haematology 2013;161(5):688-94.
2013: Maria Zingariello; Rosa Alba Rana; Laura Sancillo; Giovanni Barosi; Fiorella Ciaffoni; Emanuela D'Amore; Barbara Ghinassi; Judith D Goldberg; Xiaochun Li; Fabrizio Martelli; Francesca Masiello; Margherita Massa; Anna Rita Migliaccio
Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.
Blood 2013;121(17):3345-63.
2013: Stefania Badalucco; Giovanni Barosi; Rita Campanelli; Paolo Catarsi; Christian Andrea Di Buduo; David L Kaplan; Margherita Massa; Isabella Pallotta; Vittorio Rosti; Alessandra Balduini
Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis.
Haematologica 2013;98(4):514-7.
2013: Pier Luigi Zinzani; Giovanni Barosi; Atto Billio; Angelo Michele Carella; Mario Lazzarino; Monia Marchetti; Maurizio Martelli; Alessandro Rambaldi; Luigi Rigacci; Corrado Tarella; Sante Tura; Umberto Vitolo
SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.
American journal of hematology 2013;88(3):185-92.
2013: Vittorio Rosti; Lorenzo Tozzi; Alessandro M Vannucchi; L Villani; Orsetta Zuffardi; Giovanni Barosi; Gaetano Bergamaschi; Elisa Bonetti; Rita Campanelli; Paolo Catarsi; Elena Dallera; Giacomo Fiandrino; Gabriela Fois; Paola Guglielmelli; Marco Lucioni; Umberto Magrini; Margherita Massa; Francesca Novara; Alessandro Pancrazzi; Marco Paulli; Benedetta Peruzzi; Valentina Poletto; Roberta Riboni
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.
Blood 2013;121(2):360-8.
2013: Giovanni Barosi; Elisa Bonetti; Rita Campanelli; Paolo Catarsi; Catherine Klersy; Margherita Massa; Valentina Poletto; Gianluca Viarengo; L Villani; Vittorio Rosti
JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.
PloS one 2013;8(3):e59791.
2012: Valentina Poletto; Vittorio Rosti; Gianluca Viarengo; L Villani; Rita Campanelli; Adriana Carolei; Paolo Catarsi; Alberto Malovini; Myriam Martinetti; Margherita Massa; Anna Rita Migliaccio; Giovanni Barosi
A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation.
Blood 2012;120(15):3112-7.
2012: Giovanni Barosi
Emerging targeted therapies in myelofibrosis.
Expert review of hematology 2012;5(3):313-24.
2012: Giovanni Barosi; Atto Billio; Mario Boccadoro; Michele Cavo; Paolo Corradini; Monia Marchetti; Massimo Massaia; Giampaolo Merlini; Antonio Palumbo; Patrizia Tosi; Sante Tura
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.
Annals of hematology 2012;91(6):875-88.
2012: Omar Abdel-Wahab; Tiziano Barbui; Giovanni Barosi; Olivier A Bernard; Kapil Bhalla; Mario Cazzola; John D Crispino; Guido Finazzi; Heinz Gisslinger; Jason Gotlib; Paola Guglielmelli; Vikas Gupta; Ronald Hoffman; Jean-Jacques Kiladjian; Robert Kralovics; Tariq Mughal; Pierre Noel; Olatoyosi Odenike; Animesh Pardanani; Juergen Thiele; Richard A Van Etten; Alessandro M Vannucchi; Ayalew Tefferi
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
American journal of hematology 2012;87(5):562-8.
2012: Giovanni Barosi; Ayalew Tefferi; Tiziano Barbui
Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?
Leukemia 2012;26(5):1148-9.
2012: Francesca Romana Mauro; Giovanna Meloni; Marco Montillo; Sante Tura; Pierluigi Zinzani; Giuseppe Bandini; Giovanni Barosi; Atto Billio; Maura Brugiatelli; Antonio Cuneo; Francesco Lauria; Vincenzo Liso; Monia Marchetti
SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia.
Leukemia research 2012;36(4):459-66.
2012: Claire Harrison; Deborah S Hunter; Jean-Jacques Kiladjian; Laurent Knoops; Richard Levy; Mari McQuitty; Viktoriya Stalbovskaya; Alessandro M Vannucchi; Roger Waltzman; Haifa-Kathrin Al-Ali; Tiziano Barbui; Francisco Cervantes; Heinz Gisslinger; Giovanni Barosi
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
The New England journal of medicine 2012;366(9):787-98.
2012: Giovanni Barosi; Letizia Lupo; Vittorio Rosti
Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.
Current hematologic malignancy reports 2012;7(1):50-6.
2012: Giovanni Barosi; Elisa Bonetti; Rita Campanelli; Adriana Carolei; Paolo Catarsi; Antonina M Isgrò; Letizia Lupo; Margherita Massa; Valentina Poletto; Vittorio Rosti; Gianluca Viarengo; L Villani; Umberto Magrini
Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.
PloS one 2012;7(4):e35631.
2011: Paola Guglielmelli; Claire Hidalgo-Curtis; Amy V Jones; Margherita Maffioli; Andreas Reiter; Joannah Score; Laura Villani; Nils Winkelman; Katerina Zoi; Giovanni Barosi; Flavia Biamonte; Alberto Bosi; Francisco Cervantes; Nicholas C P Cross; Andrew Duncombe; Thomas Ernst; Tiziana Fanelli; Alessandro M Vannucchi
EZH2 mutational status predicts poor survival in myelofibrosis.
Blood 2011;118(19):5227-34.
2011: Paola Guglielmelli; Maria Letizia Lupo; Elisa Malevolti; Roberto Marchioli; Arianna Masciulli; Ubaldo Occhini; Alessandro Pancrazzi; Simona Paratore; Lisa Pieri; Alessandro Rambaldi; Maria Chiara Susini; Lorenzo Tozzi; Emilio Usala; Alessandro M Vannucchi; Elisabetta Antonioli; Tiziano Barbui; Giovanni Barosi; Niccolò Bartalucci; Flavia Biamonte; Alberto Bosi; Silvia Caglio; Guido Finazzi; Elisabetta Gattoni; Alberto Grossi
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Blood 2011;118(8):2069-76.
2011: Giovanni Barosi; Alberto Bosi; Paolo Corradini; Romano Danesi; Armando Genazzani; Fabrizio Pane; Maria P Abbracchio; Sante Tura
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.
Haematologica 2011;96(7):937-42.
2011: Giovanni Barosi; Vittorio Rosti; Alessandro M Vannucchi
Therapeutic approaches in myelofibrosis.
Expert opinion on pharmacotherapy 2011;12(10):1597-611.
2011: Valentina Achille; Giulia Arrigo; Maria Antonietta Avanzini; Giovanni Barosi; Maria Ester Bernardo; Melissa Mantelli; Francesca Novara; Marco Zecca; Orsetta Zuffardi; Rita Maccario
Cell-cycle phases and genetic profile of bone marrow-derived mesenchymal stromal cells expanded in vitro from healthy donors.
Journal of cellular biochemistry 2011;112(7):1817-21.
2011: Giovanni Barosi; Robert Peter Gale
Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: deconstructing a myth?
Leukemia research 2011;35(5):563-5.
2011: Margherita Massa; Rita Campanelli; Letizia Lupo; Gabriela Fois; Gianluca Viarengo; Vassili Jemos; Vittorio Rosti; Giovanni Barosi
Splenectomy produces a rapid but transient decrease of the frequency of circulating CD34+ haematopoietic progenitor cells in primary myelofibrosis.
British journal of haematology 2011;152(5):665-7.
2011: Tiziano Barbui; Giovanni Barosi; Gunnar Birgegård; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben A Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(6):761-70.
2011: Tiziano Barbui; Alessandra Carobbio; Guido Finazzi; Alessandro M Vannucchi; Giovanni Barosi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Pancrazzi; Silvia Salmoiraghi; Pio Zilio; Cosimo Ottomano; Roberto Marchioli; Ivan Cuccovillo; Barbara Bottazzi; Alberto Mantovani; Alessandro Rambaldi
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.
Haematologica 2011;96(2):315-8.
2011: Alessandra Balduini; Stefania Badalucco; Baev Denis; Marco Cattaneo; Annalisa De Silvestri; Maria Teresa Pugliano; Vittorio Rosti; Giovanni Barosi
In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes.
PloS one 2011;6(6):e21015.
2011: Rita Campanelli; Vittorio Rosti; L Villani; Marta Castagno; Enza Moretti; Elisa Bonetti; Gaetano Bergamaschi; Alessandra Balduini; Giovanni Barosi; Margherita Massa
Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis.
Cytokine 2011;53(1):100-6.
2010: Valeria Santini; Paolo Emilio Alessandrino; E Angelucci; Giovanni Barosi; A Billio; M Di Maio; C Finelli; F Locatelli; M Marchetti; E Morra; P Musto; G Visani; S Tura
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.
Leukemia research 2010;34(12):1576-88.
2010: Giovanni Barosi; Umberto Magrini; Robert Peter Gale
Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?
Leukemia research 2010;34(9):1119-20.
2010: Alessandra Carobbio; Guido Finazzi; Elisabetta Antonioli; Alessandro M Vannucchi; Giovanni Barosi; Marco Ruggeri; Francesco Rodeghiero; Federica Delaini; Alessandro Rambaldi; Tiziano Barbui
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria.
Blood 2010;116(7):1051-5.
2010: Alessandro Rambaldi; Chiara Maria Dellacasa; Guido Finazzi; Alessandra Carobbio; Maria Luisa Ferrari; Paola Guglielmelli; Elisabetta Gattoni; Silvia Salmoiraghi; Maria Chiara Finazzi; Silvia Di Tollo; Carmine D'Urzo; Alessandro M Vannucchi; Giovanni Barosi; Tiziano Barbui
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.
British journal of haematology 2010;150(4):446-55.
2010: Giovanni Barosi; Elisabetta Gattoni; Paola Guglielmelli; Rita Campanelli; Fabio Facchetti; Simona Fisogni; Judith Goldberg; Roberto Marchioli; Ronald Hoffman; Alessandro M Vannucchi
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.
American journal of hematology 2010;85(8):616-9.
2010: Paola Guglielmelli; F Biamonte; A Spolverini; L Pieri; A Isgrò; Elisabetta Antonioli; Alessandro Pancrazzi; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis.
Leukemia 2010;24(8):1533-7.
2010: Giovanni Barosi; Gunnar Birgegård; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Hasselbalch; Jean-Jacques Kiladijan; Eva Lengfelder; Ruben Mesa; Mary F Mc Mullin; Francesco Passamonti; John T Reilly; Alessandro M Vannucchi; Tiziano Barbui
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.
British journal of haematology 2010;148(6):961-3.
2010: Umberto Vitolo; Giovanni Barosi; Stefano Fanti; ALESSANDRO MASSIMO GIANNI; Maurizio Martelli; Mario Petrini; Pier Luigi Zinzani; Sante Tura
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology.
American journal of hematology 2010;85(2):147-55.
2010: Tiziano Barbui; Alessandra Carobbio; Francisco Cervantes; Alessandro M Vannucchi; Paola Guglielmelli; Elisabetta Antonioli; Alberto Alvarez-Larrán; Alessandro Rambaldi; Guido Finazzi; Giovanni Barosi
Thrombosis in primary myelofibrosis: incidence and risk factors.
Blood 2010;115(4):778-82.
2010: Vittorio Rosti; Elisa Bonetti; Gaetano Bergamaschi; Rita Campanelli; Paola Guglielmelli; Marcello Maestri; Umberto Magrini; Margherita Massa; Carmine Tinelli; Gianluca Viarengo; L Villani; Massimo Primignani; Alessandro M Vannucchi; Francesco Frassoni; Giovanni Barosi
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis.
PloS one 2010;5(12):e15277.
2009: Corrado Girmenia; Giovanni Barosi; Franco Aversa; Andrea Bacigalupo; Tiziano Barbui; Donatella Baronciani; Alberto Bosi; Anna Candoni; Anna Locasciulli; Franco Locatelli; Francesco Menichetti; Maurizio Musso; Claudio Viscoli; Alessandro Rambaldi
Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(8):1226-36.
2009: Giovanna Piaggio; Vittorio Rosti; Mirko Corselli; Francesca Bertolotti; Gaetano Bergamaschi; Sarah Pozzi; Davide Imperiale; Barbara Chiavarina; Elisa Bonetti; Francesca Novara; Mario Sessarego; Laura Villani; Anna Garuti; Margherita Massa; Riccardo Ghio; Rita Campanelli; Andrea Bacigalupo; Alessandro Pecci; Gianluca Viarengo; Orsetta Zuffardi; Francesco Frassoni; Giovanni Barosi
Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker.
Blood 2009;114(14):3127-30.
2009: Ayalew Tefferi; Srdan Verstovsek; Giovanni Barosi; Francesco Passamonti; Gail J Roboz; Heinz Gisslinger; Ronald L Paquette; Francisco Cervantes; Candido E Rivera; H Joachim Deeg; Juergen Thiele; Hans Michael Kvasnicka; James W Vardiman; Yanming Zhang; B Nebiyou Bekele; Ruben A Mesa; Robert P Gale; Hagop M Kantarjian
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(27):4563-9.
2009: Paola Guglielmelli; Giovanni Barosi; Giorgina Specchia; Alessandro Rambaldi; Francesco Lo Coco; Elisabetta Antonioli; Lisa Pieri; Alessandro Pancrazzi; Vanessa Ponziani; Federica Delaini; Giovanni Longo; Emanuele Ammatuna; Vincenzo Liso; Alberto Bosi; Tiziano Barbui; Alessandro M Vannucchi
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
Blood 2009;114(8):1477-83.
2009: Giovanni Barosi; Gunnar Birgegård; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Jean-Jacques Kiladjian; Eva Lengfelder; Mary Frances McMullin; Francesco Passamonti; John T Reilly; Alessandro M Vannucchi; Tiziano Barbui
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.
Blood 2009;113(20):4829-33.
2009: Ercole Brusamolino; Andrea Bacigalupo; Giovanni Barosi; Giampaolo Biti; Paolo G Gobbi; Alessandro Levis; Monia Marchetti; Armando Santoro; Pier Luigi Zinzani; Sante Tura
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up.
Haematologica 2009;94(4):550-65.
2009: Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Blood 2009;113(13):2895-901.
2009: Giovanni Barosi; Vittorio Rosti
Novel strategies for patients with chronic myeloproliferative disorders.
Current opinion in hematology 2009;16(2):129-34.
2009: Claudio Grignani; Patrizia Noris; Carmine Tinelli; Giovanni Barosi; Carlo L Balduini
In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: are they laboratory artefacts?
Platelets 2009;20(2):131-4.
2009: Paola Guglielmelli; Giovanni Barosi; Lisa Pieri; Elisabetta Antonioli; Alberto Bosi; Alessandro M Vannucchi
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.
Haematologica 2009;94(1):144-6.
2009: Enrica Morra; Giovanni Barosi; Alberto Bosi; Felicetto Ferrara; Franco Locatelli; Monia Marchetti; giovanni martinelli; Cristina Mecucci; Marco Vignetti; Sante Tura
Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.
Haematologica 2009;94(1):102-12.
2008: Patrizia Tosi; Giovanni Barosi; Carlo Lazzaro; Vincenzo Liso; Monia Marchetti; Enrica Morra; Andrea Pession; Giovanni Rosti; Antonio Santoro; Pier Luigi Zinzani; Sante Tura
Consensus conference on the management of tumor lysis syndrome.
Haematologica 2008;93(12):1877-85.
2008: Alessandro Pancrazzi; Paola Guglielmelli; Vanessa Ponziani; Gaetano Bergamaschi; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.
The Journal of molecular diagnostics : JMD 2008;10(5):435-41.
2008: Pier Luigi Zinzani; Maurizio Martelli; Venerino Poletti; Umberto Vitolo; Paolo G Gobbi; Tommaso Chisesi; Giovanni Barosi; Andrés J M Ferreri; Monia Marchetti; Nicola Pimpinelli; Sante Tura
Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Haematologica 2008;93(9):1364-71.
2008: Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Pancrazzi; Vittoria Guerini; Giovanni Barosi; Marco Ruggeri; Giorgina Specchia; Francesco Lo Coco; Federica Delaini; Laura Villani; Silvia Finotto; Emanuele Ammatuna; Renato Alterini; Valentina Carrai; Gloria Capaccioli; Simonetta Di Lollo; Vincenzo Liso; Alessandro Rambaldi; Alberto Bosi; Tiziano Barbui
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.
Blood 2008;112(3):844-7.
2008: Costanza Bogani; Vanessa Ponziani; Paola Guglielmelli; desterke christophe; Vittorio Rosti; Alberto Bosi; Marie-Caroline Le Bousse-Kerdilès; Giovanni Barosi; Alessandro M Vannucchi
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis.
Stem cells (Dayton, Ohio) 2008;26(8):1920-30.
2008: Emanuele Angelucci; Giovanni Barosi; Clara Camaschella; Maria Domenica Cappellini; Mario Cazzola; Renzo Galanello; Monia Marchetti; Antonio Piga; Sante Tura
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.
Haematologica 2008;93(5):741-52.
2008: Francisco Cervantes; Francesco Passamonti; Giovanni Barosi
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.
Leukemia 2008;22(5):905-14.
2008: Gaetano M Bergamaschi; Massimo Primignani; Giovanni Barosi; Federica M Fabris; Laura Villani; Raffaella Reati; Alessandra Dell'era; Pier M Mannucci
MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction.
Blood 2008;111(8):4418.
2008: Giovanni Barosi; Ruben A Mesa; J Thiele; Francisco Cervantes; Peter J Campbell; Srdan Verstovsek; Brigitte Dupriez; Ross Levine; Francesco Passamonti; J Gotlib; John T Reilly; A M Vannucchi; C A Hanson; Lawrence Solberg; A Orazi; Ayalew Tefferi
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
Leukemia 2008;22(2):437-8.
2007: Giovanni Barosi; Gaetano Bergamaschi; Monia Marchetti; Alessandro M Vannucchi; Paola Guglielmelli; Elisabetta Antonioli; Margherita Massa; Vittorio Rosti; Rita Campanelli; Laura Villani; Gianluca Viarengo; Elisabetta Gattoni; Giancarla Gerli; Giorgina Specchia; Carmine Tinelli; Alessandro Rambaldi; Tiziano Barbui
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.
Blood 2007;110(12):4030-6.
2007: Francisco Cervantes; Ruben Mesa; Giovanni Barosi
New and old treatment modalities in primary myelofibrosis.
Cancer journal (Sudbury, Mass.) 2007;13(6):377-83.
2007: Emanuela Maserati; Barbara Pressato; Roberto Valli; Francesco Patitucci; Francesco Lo Curto; Francesco Pasquali; Antonella Minelli; Cesare Danesino; Monia Marchetti; Giovanni Barosi
Constitutional trisomy 8 mosaicism in primary myelofibrosis: relevance to clinical practice and warning for trisomy 8 studies.
Cancer genetics and cytogenetics 2007;179(1):79-81.
2007: Giovanni Barosi
New consensus: a unified definition of clinical resistance and/or intolerance to hydroxyurea in essential thrombocythaemia.
European journal of haematology. Supplementum 2007;(68):24-6.
2007: Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegård; Ruben A Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Blood 2007;110(4):1092-7.
2007: Stefan O Ciurea; Delwin Merchant; Nadim Mahmud; Takefumi Ishii; Yan Zhao; WENYANG HU; Edward Bruno; Giovanni Barosi; Mingjiang Xu; Ronald Hoffman
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.
Blood 2007;110(3):986-93.
2007: Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Rambaldi; Giovanni Barosi; Roberto Marchioli; Rosa Maria Marfisi; Guido Finazzi; Vittoria Guerini; Fabrizio Fabris; Maria Luigia Randi; Valerio De Stefano; Sabrina Caberlon; Agostino Tafuri; Marco Ruggeri; Giorgina Specchia; Vincenzo Liso; Edoardo Rossi; Enrico Pogliani; Luigi Gugliotta; Alberto Bosi; Tiziano Barbui
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
Blood 2007;110(3):840-6.
2007: Ruben A Mesa; Srdan Verstovsek; Francisco Cervantes; Giovanni Barosi; John T Reilly; Brigitte Dupriez; Ross Levine; Marie-Caroline Le Bousse-Kerdiles; Martha Wadleigh; Peter J Campbell; Richard T Silver; Alessandro M Vannucchi; H Joachim Deeg; Heinz Gisslinger; Deborah Thomas; Olatoyosi Odenike; Lawrence Solberg; Jason Gotlib; Elizabeth Hexner; Stephen D Nimer; Andrew Lamb; Attilio Orazi; James W Vardiman; Juergen Thiele; Ayalew Tefferi
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Leukemia research 2007;31(6):737-40.
2007: Paola Guglielmelli; Alessandro Pancrazzi; Gaetano Bergamaschi; Vittorio Rosti; Laura Villani; Elisabetta Antonioli; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.
British journal of haematology 2007;137(3):244-7.
2007: Vittorio Rosti; Margherita Massa; Alessandro M Vannucchi; Gaetano Bergamaschi; Rita Campanelli; Alessandro Pecci; Gianluca Viarengo; Valentina Meli; Monia Marchetti; Paola Guglielmelli; Edward Bruno; Mingjiang Xu; Ronald Hoffman; Giovanni Barosi
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia.
Blood cells, molecules & diseases 2007;38(3):280-6.
2007: Nicola Liberato; Monia Marchetti; Giovanni Barosi
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(6):625-33.
2007: Giovanni Barosi; C Besses; Gunnar Birgegård; Jean Briere; Francisco Cervantes; Guido Finazzi; Heinz Gisslinger; Martin Griesshammer; Luigi Gugliotta; C Harrison; Hans Carl Hasselbalch; Eva Lengfelder; John T Reilly; JJ Michiels; Tiziano Barbui
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.
Leukemia 2007;21(2):277-80.
2007: Tapani Ruutu; Giovanni Barosi; Richard J Benjamin; Richard E Clark; James N George; Alois Gratwohl; Ernst Holler; Massimo Iacobelli; Karim Kentouche; Bernhard Lämmle; Joel L Moake; Paul Richardson; Gérard Socié; Zella R Zeigler; Dietger Niederwieser; Tiziano Barbui
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.
Haematologica 2007;92(1):95-100.
2007: Paola Guglielmelli; Roberta Zini; Costanza Bogani; Simona Salati; Alessandro Pancrazzi; Elisa Bianchi; Francesco Mannelli; Sergio Ferrari; Marie-Caroline Le Bousse-Kerdilès; Alberto Bosi; Giovanni Barosi; Anna Rita Migliaccio; Rossella Manfredini; Alessandro M Vannucchi
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).
Stem cells (Dayton, Ohio) 2007;25(1):165-73.
2006: Maura Brugiatelli; Giuseppe Bandini; Giovanni Barosi; Francesco Lauria; Vincenzo Liso; Monia Marchetti; Francesca Romana Mauro; Giovanna Meloni; Pier Luigi Zinzani; Sante Tura
Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Haematologica 2006;91(12):1662-73.
2006: Massimo Primignani; Giovanni Barosi; Gaetano Bergamaschi; Umberto Gianelli; Federica Fabris; Raffaella Reati; Alessandra Dell'era; Paolo Bucciarelli; Pier Mannuccio Mannucci
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
Hepatology (Baltimore, Md.) 2006;44(6):1528-34.
2006: Ayalew Tefferi; Giovanni Barosi; Ruben A Mesa; Francisco Cervantes; H Joachim Deeg; John T Reilly; Srdan Verstovsek; Brigitte Dupriez; Richard T Silver; Olatoyosi Odenike; Jorge Cortes; Martha Wadleigh; Lawrence Solberg; John K Camoriano; Heinz Gisslinger; Pierre Noel; Juergen Thiele; James W Vardiman; Ronald Hoffman; Nicholas C P Cross; D Gary Gilliland; Andrew Lamb
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Blood 2006;108(5):1497-503.
2006: Hongyu Ni; Giovanni Barosi; Ronald Hoffman
Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis.
American journal of clinical pathology 2006;126(2):241-7.
2006: Giovanni Barosi; Andrea Bacigalupo
Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Current opinion in hematology 2006;13(2):74-8.
2006: Ruben A Mesa; Giovanni Barosi; Francisco Cervantes; John T Reilly; Ayalew Tefferi
Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.
Best practice & research. Clinical haematology 2006;19(3):495-517.
2006: Giovanni Barosi; Angelo Carella; Mario Lazzarino; Monia Marchetti; Maurizio Martelli; Alessandro Rambaldi; Corrado Tarella; Umberto Vitolo; Pier Luigi Zinzani; Sante Tura
Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Haematologica 2006;91(1):96-103.
2005: Giovanni Barosi; Dominique Bordessoule; Jean Briere; Francisco Cervantes; Jean-Loup Demory; Brigitte Dupriez; Heinz Gisslinger; Martin Griesshammer; Hans Carl Hasselbalch; Rajko Kusec; Marie-Caroline Le Bousse-Kerdiles; Nicola Liberato; Monia Marchetti; John T Reilly; Juergen Thiele
Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET).
Blood 2005;106(8):2849-53.
2005: Giovanni Barosi; Ronald Hoffman
Idiopathic myelofibrosis.
Seminars in hematology 2005;42(4):248-58.
2005: Giovanni Barosi; Angelo Carella; Mario Lazzarino; Monia Marchetti; Maurizio Martelli; Alessandro Rambaldi; Corrado Tarella; Umberto Vitolo; Pier Luigi Zinzani; Sante Tura
Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation.
Haematologica 2005;90(9):1236-57.
2005: Margherita Massa; Vittorio Rosti; Isabella Ramajoli; Rita Campanelli; Alessandro Pecci; Gianluca Viarengo; Valentina Meli; Monia Marchetti; Ronald Hoffman; Giovanni Barosi
Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5688-95.
2005: Francisco Cervantes; Giovanni Barosi
Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging.
Seminars in oncology 2005;32(4):395-402.
2005: Hongyu Ni; Giovanni Barosi; Damiano Rondelli; Ronald Hoffman
Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis.
American journal of clinical pathology 2005;123(6):833-9.
2005: Mingjiang Xu; Edward Bruno; Joseph Chao; Stephen Huang; Guido Finazzi; Steven Fruchtman; Uday Popat; Josef T Prchal; Giovanni Barosi; Ronald Hoffman
Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases.
Blood 2005;105(11):4508-15.
2005: Damiano Rondelli; Giovanni Barosi; Andrea Bacigalupo; Josef T Prchal; Uday Popat; Emilio Paolo Alessandrino; Jerry L Spivak; B Douglas Smith; Hans G Klingemann; Steven Fruchtman; Ronald Hoffman
Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia.
Blood 2005;105(10):4115-9.
2005: Mingjiang Xu; Edward Bruno; Joseph Chao; Hongyu Ni; Valerie Lindgren; Rafael Nunez; Nadim Mahmud; Guido Finazzi; Steven Fruchtman; Uday Popat; Enli Liu; Josef T Prchal; Damiano Rondelli; Giovanni Barosi; Ronald Hoffman
The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis.
Blood 2005;105(4):1699-705.
2004: Giovanni Barosi; Mario Boccadoro; Michele Cavo; Paolo Corradini; Monia Marchetti; Massimo Massaia; Giampaolo Merlini; Patrizia Tosi; Sante Tura
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).
Haematologica 2004;89(6):717-41.
2004: Giovanni Barosi; Vittorio Rosti; Margherita Massa; Gianluca Viarengo; Alessandro Pecci; Vittorio Necchi; Isabella Ramaioli; Rita Campanelli; Monia Marchetti; Mario Bazzan; Umberto Magrini
Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia.
British journal of haematology 2004;124(5):618-25.
2004: Tiziano Barbui; Giovanni Barosi; Alberto Grossi; Luigi Gugliotta; Nicola Liberato; Monia Marchetti; Maria Gabriella Mazzucconi; Francesco Rodeghiero; Sante Tura
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Haematologica 2004;89(2):215-32.
2004: Monia Marchetti; Giovanni Barosi; Francesca Balestri; Gianluca Viarengo; Sara Gentili; Sara Barulli; Jean-Loup Demory; Fiorella Ilariucci; Antonio Volpe; Dominique Bordessoule; Alberto Grossi; Marie-Caroline Le Bousse-Kerdiles; Andrea Caenazzo; Alessandro Pecci; Antonietta Falcone; Giorgio Broccia; Cesarina Bendotti; Fredric Bauduer; Francesco Buccisano; Brigitte Dupriez
Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(3):424-31.
2004: Monia Marchetti; Giovanni Barosi
Clinical and economic impact of epoetins in cancer care.
PharmacoEconomics 2004;22(16):1029-45.
2003: Giovanni Barosi
Myelofibrosis with myeloid metaplasia.
Hematology/oncology clinics of North America 2003;17(5):1211-26.
2003: Jerry L Spivak; Giovanni Barosi; Gianni Tognoni; Tiziano Barbui; Guido Finazzi; Roberto Marchioli; Monia Marchetti
Chronic myeloproliferative disorders.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2003;():200-24.
2003: Nicola Liberato; Monia Marchetti; Giovanni Barosi
Clinical and economic issues in the treatment of advanced breast cancer with bisphosphonates.
Drugs & aging 2003;20(9):631-42.
2002: Emilio Paolo Alessandrino; Sergio Amadori; Giovanni Barosi; Mario Cazzola; Alberto Grossi; Nicola Liberato; Franco Locatelli; Monia Marchetti; Enrica Morra; Paolo Rebulla; Giuseppe Visani; Sante Tura
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
Haematologica 2002;87(12):1286-306.
2002: Monia Marchetti; Giovanni Barosi
Screening for factor V Leiden mutation in pregnant women.
Lancet 2002;360(9344):1518.
2002: Giovanni Barosi; Laura Salvaneschi; Maurizia Grasso; Miryam Martinetti; Monia Marchetti; Umberto Bodini; Alessandro Reggiani; Francesco D'Agostino; Giulio Nalli; Alberto Degiuli; Annalisa De Silvestri; Eloisa Arbustini
High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy.
Haematologica 2002;87(5):472-8.
2001: Giovanni Barosi; Gianluca Viarengo; Alessandro Pecci; Vittorio Rosti; Giovanna Piaggio; Monia Marchetti; Francesco Frassoni
Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.
Blood 2001;98(12):3249-55.
2001: Giancarla Gerli; Umberto Gianelli; Maria Cristina Carraro; A Bestetti; Monia Marchetti; Giovanni Barosi
Myelofibrosis with myeloid metaplasia with fatty bone marrow: report of a new case.
Haematologica 2001;86(8):885-6.
2001: Monia Marchetti; A Pistorio; M Barone; S Serafini; Giovanni Barosi
Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis.
The American journal of medicine 2001;111(2):130-9.
2001: Giovanni Barosi; A Grossi; B Comotti; P Musto; G Gamba; Monia Marchetti
Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.
British journal of haematology 2001;114(1):78-83.
2001: Monia Marchetti; Silvana Quaglini; Giovanni Barosi
Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A.
QJM : monthly journal of the Association of Physicians 2001;94(7):365-72.
2001: M Marchetti; Giovanni Barosi; Nicola Liberato
Fludarabine for chronic lymphocytic leukemia.
The New England journal of medicine 2001;344(15):1166-7; author reply 1167-8.
2000: Monia Marchetti; A Pistorio; Giovanni Barosi
Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis.
Thrombosis and haemostasis 2000;84(5):752-7.
1999: Giovanni Barosi
Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2954-70.
1999: Silvana Quaglini; L Dazzi; Mario Stefanelli; Giovanni Barosi; Monia Marchetti
Decision support systems in health economics.
Topics in health information management 1999;20(1):16-30.
1999: Monia Marchetti; Nicola Liberato; N Ruperto; Giovanni Barosi
Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement.
Haematologica 1999;84(8):730-7.
1999: Giovanni Barosi; A Ambrosetti; Carlo Finelli; A Grossi; Pietro Leoni; Nicola Liberato; M C Petti; Enrico Pogliani; Maria M Ricetti; Serena Rupoli; Giuseppe Visani; S Tura
The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia.
British journal of haematology 1999;104(4):730-7.
1998: Monia Marchetti; Silvana Quaglini; Giovanni Barosi
Prophylactic splenectomy and cholecystectomy in mild hereditary spherocytosis: analyzing the decision in different clinical scenarios.
Journal of internal medicine 1998;244(3):217-26.
1998: Giovanni Barosi; Monia Marchetti; Nicola Liberato
Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.
British journal of cancer 1998;78(6):781-7.
1998: Francisco Cervantes; Giovanni Barosi; Jean-Loup Demory; J Reilly; R Guarnone; Brigitte Dupriez; Arturo Pereira; Emili Montserrat
Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups.
British journal of haematology 1998;102(3):684-90.
1998: E Centenara; R Guarnone; G Ippoliti; Giovanni Barosi
Cyclosporin-A in severe refractory anemia of myelofibrosis with myeloid metaplasia: a preliminary report.
Haematologica 1998;83(7):622-6.
1998: Giovanni Barosi; A Ambrosetti; A Centra; A Falcone; Carlo Finelli; P Foa; A Grossi; R Guarnone; Serena Rupoli; L Luciano; M C Petti; Enrico Pogliani; D Russo; M Ruggeri; S Quaglini
Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia.
Blood 1998;91(10):3630-6.
1997: Giovanni Barosi; Monia Marchetti; L Dazzi; Silvana Quaglini
Testing for occult cancer in patients with idiopathic deep vein thrombosis--a decision analysis.
Thrombosis and haemostasis 1997;78(5):1319-26.
1997: Mario Cazzola; Gaetano Bergamaschi; L Tonon; Eloisa Arbustini; M Grasso; E Vercesi; Giovanni Barosi; Paolo Emilio Bianchi; G Cairo; Paolo Arosio
Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA.
Blood 1997;90(2):814-21.
1997: Nicola Liberato; S Quaglini; Giovanni Barosi
Cost-effectiveness of interferon alfa in chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2673-82.
1996: Mario Cazzola; Luisa Ponchio; de benedetti fabrizio; Angelo Ravelli; Vittorio Rosti; Yves Beguin; Rosangela Invernizzi; Giovanni Barosi; Alberto Martini
Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis.
Blood 1996;87(11):4824-30.
1996: Monia Marchetti; Nicola Liberato; Giovanni Barosi
Beyond Bayes.
Haematologica 1996;81(3):253-7.
1996: R Guarnone; E Centenara; M Zappa; A Zanella; Giovanni Barosi
Erythropoietin production and erythropoiesis in compensated and anaemic states of hereditary spherocytosis.
British journal of haematology 1996;92(1):150-4.
1995: R Guarnone; E Centenara; Giovanni Barosi
Performance characteristics of Hemox-Analyzer for assessment of the hemoglobin dissociation curve.
Haematologica 1995;80(5):426-30.
1995: Giovanni Barosi; M Marchetti; F Piovella; S Quaglini
Cost-effectiveness of post-routine screening for an occult cancer in patients with idiopathic venous thromboembolism.
Haematologica 1995;80(2 Suppl):61-5.
1994: Alberto Martini; Angelo Ravelli; G Di Fuccia; Vittorio Rosti; Mario Cazzola; Giovanni Barosi
Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis.
Lancet 1994;344(8929):1052-4.
1994: Caterina Borgna-Pignatti; Nicola Liberato; Pier Luigi Marradi; Vittorio Rosti; Giovanni Barosi
Regulation of erythropoietin production in a case of congenital erythropoietin-dependent pure erythrocytosis.
American journal of hematology 1994;46(4):348-53.
1994: Renzo Galanello; Susanna Barella; M P Turco; Nicolina Giagu; Antonio Cao; F Dore; Nicola Liberato; R Guarnone; Giovanni Barosi
Serum erythropoietin and erythropoiesis in high- and low-fetal hemoglobin beta-thalassemia intermedia patients.
Blood 1994;83(2):561-5.
1993: Alberto Zanella; A Berzuini; M B Colombo; A Guffanti; Lucilla Lecchi; Francesca Poli; M D Cappellini; Giovanni Barosi
Iron status in red cell pyruvate kinase deficiency: study of Italian cases.
British journal of haematology 1993;83(3):485-90.
1993: Giovanni Barosi; L N Liberato; R Guarnone
Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia.
British journal of haematology 1993;83(3):365-9.
1993: Giovanni Barosi; Achille Ambrosetti; A Buratti; Carlo Finelli; Nicola Liberato; S Quaglini; Maria M Ricetti; Giuseppe Visani; S Tura; Edoardo Ascari
Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction.
Leukemia 1993;7(2):200-6.
1993: Giovanni Barosi; C Merlo; P Palestra; Nicola Liberato; R Guarnone; F Di Dio; Valter Piazza; Alessandro Salvadeo
Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
Acta haematologica 1993;90(1):13-8.
1992: Franco Locatelli; Paolo Pedrazzoli; Giovanni Barosi; Marco Zecca; Fulvio Porta; L Liberato; D Gambarana; L Nespoli; Mario Cazzola
Recombinant human erythropoietin is effective in correcting erythropoietin-deficient anaemia after allogeneic bone marrow transplantation.
British journal of haematology 1992;80(4):545-9.
1992: Mario Cazzola; Luisa Ponchio; Yves Beguin; Vittorio Rosti; Gaetano Bergamaschi; Nicola Liberato; V Fregoni; G Nalli; Giovanni Barosi; Edoardo Ascari
Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial.
Blood 1992;79(1):29-37.
1992: Valter Piazza; F Poggio; C Merlo; P Palestra; Giovanni Barosi; Alessandro Salvadeo
Analysis of serum ferritin changes during erythropoietin therapy in haemodialysis patients.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1992;7(12):1254-6.
1992: Valter Piazza; Giuseppe Villa; F Galli; Siro Segagni; G Bovio; F Poggio; L Picardi; L Bianco; Alessandro Salvadeo; Giovanni Barosi
Erythropoietin as treatment of haemodialysis-related porphyria cutanea tarda.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1992;7(5):438-42.
1991: Giovanni Barosi; A Buratti; A Costa; L N Liberato; C Balduini; Mario Cazzola; Vittorio Rosti; Umberto Magrini; Edoardo Ascari
An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression.
Cancer 1991;68(10):2310-8.
1991: A Costa; L N Liberato; P Palestra; Giovanni Barosi
Small-dose iron tolerance test and body iron content in normal subjects.
European journal of haematology 1991;46(3):152-7.
1990: G Lanzola; Mario Stefanelli; Giovanni Barosi; L Magnani
NEOANEMIA: a knowledge-based system emulating diagnostic reasoning.
Computers and biomedical research, an international journal 1990;23(6):560-82.
1990: Valter Piazza; F Galli; Giuseppe Villa; Alessandro Salvadeo; V Battistel; Giovanni Barosi
Erythropoietin, aluminium, and anaemia in patients on haemodialysis.
Lancet 1990;336(8709):255-6.
1990: Nicola Liberato; A Costa; Giovanni Barosi
Erythropoietin: biological aspects and clinical usefulness.
Haematologica 1990;75(4):346-62.
1990: Giovanni Barosi; Nicola Liberato; A Costa; Edoardo Ascari
[Cytoreductive effect of recombinant alfa-interferon in patients with myelofibrosis with myeloid metaplasia].
Haematologica 1990;75 Suppl 4():48-50.
1990: C Del Forno; G Borroni; G Caresana; G Nalli; Giovanni Barosi
[Cutaneous extramedullary hematopoiesis in idiopathic myelofibrosis. Description of a case].
Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia 1990;125(5):205-9.
1990: A Costa; Giovanni Barosi; G Piccolo; E Nobile-Orazio; Nicola Liberato; Edoardo Ascari
POEMS syndrome with IgA lambda monoclonal gammopathy.
Haematologica 1990;75(2):170-2.
1990: Giovanni Barosi; L N Liberato; A Costa; A Buratti; F Di Dio; S Salvatore; Edoardo Ascari
Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia.
European journal of haematology. Supplementum 1990;52():12-4.
1989: Giovanni Barosi; L N Liberato; A Costa; Edoardo Ascari
Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia.
Blut 1989;58(6):271-4.
1989: Alberto Zanella; Giovanni Barosi; A Berzuini; M B Colombo; Silvana Quaglini; D Volpes; Girolamo Sirchia
Relative iron deficiency in hereditary spherocytosis.
American journal of hematology 1989;31(2):81-6.
1989: Giovanni Barosi; A Costa; L N Liberato; G Polino; P Spriano; Umberto Magrini
Serum procollagen-III-peptide level correlates with disease activity in myelofibrosis with myeloid metaplasia.
British journal of haematology 1989;72(1):16-20.
1989: Giovanni Barosi; Eloisa Arbustini; Antonello Gavazzi; Maurizia Grasso; A Pucci
Myocardial iron grading by endomyocardial biopsy. A clinico-pathologic study on iron overloaded patients.
European journal of haematology 1989;42(4):382-8.
1989: Nicola Liberato; Giovanni Barosi; A Costa; P D'Elia; P Boccaccio
Myelofibrosis with myeloid metaplasia following essential thrombocythaemia.
Acta haematologica 1989;82(3):150-3.
1988: Giovanni Barosi; C Berzuini; L N Liberato; A Costa; G Polino; Edoardo Ascari
A prognostic classification of myelofibrosis with myeloid metaplasia.
British journal of haematology 1988;70(4):397-401.
1988: Carlo L Balduini; G Bertolino; G Gamba; Giovanni Barosi; Fabiola Sinigaglia; Patrizia Noris; A Bisio; Edoardo Ascari
Platelet aggregation in platelet rich plasma and whole blood in 18 patients affected by idiopathic myelofibrosis.
European journal of haematology 1988;41(3):267-72.
1988: Silvana Quaglini; Mario Stefanelli; Giovanni Barosi; A Berzuini
A performance evaluation of the expert system ANEMIA.
Computers and biomedical research, an international journal 1988;21(4):307-23.
1988: Mario Cazzola; Giovanni Barosi; Paolo G Gobbi; Rosangela Invernizzi; A Riccardi; Edoardo Ascari
Natural history of idiopathic refractory sideroblastic anemia.
Blood 1988;71(2):305-12.
1987: Giovanni Barosi; C Berzuini; A Costa; Nicola Liberato; G Polino; Edoardo Ascari
Myelofibrosis with myeloid metaplasia and history of malaria.
Lancet 1987;2(8567):1094-5.
1987: Giovanni Barosi; G Polino
Chronic myelofibrosis with myeloid metaplasia. The spectrum of clinical syndromes.
Haematologica 1987;72(6):553-62.
1987: C Carlo-Stella; Mario Cazzola; A Gasner; Giovanni Barosi; L Dezza; F Meloni; Paolo Pedrazzoli; Dieter Hoelzer; Edoardo Ascari
Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia.
Blood 1987;70(4):1014-9.
1987: Giovanni Barosi; L Mascaretti; Caterina Borgna-Pignatti; Piero De Stefano; P Palestra; G Polino; Silvana Quaglini; F Rossi
The relationship between erythropoiesis, foetal haemoglobin and clinical manifestations in thalassaemia intermedia.
Haematologica 1987;72(5):421-4.
1986: G Polino; Giovanni Barosi; A Berzuini; G Castelli; P Isernia; P Palestra; A Riccardi; F Rossi; Umberto Magrini
Fatty bone marrow with severe myeloid hypoplasia in idiopathic myelofibrosis.
Haematologica 1986;71(2):117-21.
1986: Silvana Quaglini; Mario Stefanelli; Giovanni Barosi; A Berzuini
ANEMIA: an expert consultation system.
Computers and biomedical research, an international journal 1986;19(1):13-27.
1986: P Spriano; Giovanni Barosi; Rosangela Invernizzi; G Ippoliti; A Fortunato; R Rosso; Umberto Magrini
Splenomegalic immunocytoma with circulating hairy cells. Report of eight cases and revision of the literature.
Haematologica 1986;71(1):25-33.
1985: Giovanni Barosi; M Cazzola; C Berzuini; Silvana Quaglini; Mario Stefanelli
Classification of anaemia on the basis of ferrokinetic parameters.
British journal of haematology 1985;61(2):357-70.
1985: Giovanni Barosi; A Berzuini; Silvana Quaglini; M Stefanelli
Anemia: an artificial intelligence project.
Haematologica 1985;70(4):358-62.
1984: Giovanni Barosi; A Baraldi; G Bellomo; M Cazzola; A P Martino; P Palestra; P Spriano; P Fratino
Increased whole body hematocrit: venous hematocrit ratio in diabetes mellitus, evidence of microcirculatory hemoconcentration.
Acta diabetologica latina 1984;21(3):257-62.
1984: Giovanni Barosi; A Baraldi; A Berzuini; L Mascaretti; P Palestra; G Polino; S Ramella; F Rossi; P Spriano; I Cavill
The influence of regional haematocrit on "in vivo" ferrokinetic measurements.
Haematologica 1984;69(4):410-20.
1984: Giovanni Barosi; A Baraldi; M Cazzola; A Fortunato; P Palestra; G Polino; S Ramella; P Spriano
Polycythaemia following splenectomy in myelofibrosis with myeloid metaplasia. A reorganization of erythropoiesis.
Scandinavian journal of haematology 1984;32(1):12-8.
1984: P Spriano; A Baraldi; Giovanni Barosi; Rosangela Invernizzi; G Ippoliti; L Mascaretti; P Palestra; G Polino; S Ramella; R Rosso
Malignant lymphoma with hairy cells and IgM paraprotein. Splenic homing of secreting cells.
Haematologica 1984;69(1):71-9.
1983: Giovanni Barosi; A Baraldi; F Bonomi; M Cazzola; M Dacco; P Spriano; M Stefanelli
Competing models for the analysis of red cell survival obtained with 51Cr labelling technique.
Scandinavian journal of haematology 1983;31(4):381-8.
1983: Giovanni Barosi; A Baraldi; M Cazzola; P Spriano; Umberto Magrini
Red cell aplasia in myelofibrosis with myeloid metaplasia. A distinct functional and clinical entity.
Cancer 1983;52(7):1290-6.
1983: M Cazzola; Giovanni Barosi; Gaetano Bergamaschi; L Dezza; P Palestra; G Polino; S Ramella; P Spriano; Edoardo Ascari
Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias.
British journal of haematology 1983;54(4):649-54.
1982: Giovanni Barosi; P Alessandrino; Giampaolo Merlini; E Orlandi; P Spriano
Non-tropical idiopathic splenomegaly. Report of a case.
Haematologica 1982;67(2):255-60.
1982: E Orlandi; P Alessandrino; A Baraldi; Giovanni Barosi; C Berzuini; M Cazzola; P Spriano
Erythropoiesis in hairy cell leukaemia: a true erythroid failure.
Scandinavian journal of haematology 1982;28(2):97-102.
1982: M Cazzola; Giovanni Barosi; C Berzuini; M Dacco; E Orlandi; Mario Stefanelli; Edoardo Ascari
Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes.
British journal of haematology 1982;50(1):55-62.
1980: M Cazzola; P Alessandrino; Giovanni Barosi; E Orlandi; Edoardo Ascari
Iron loading in beta-thalassaemia.
Lancet 1980;1(8161):204.